Compounds for treatment of cystic fibrosis

Rhalid Akkari, Pantin, FR;

Luke Jonathan Alvey, Versailles, FR;

Xavier Marie Bock, Romainville, FR;

Brian S. Brown, Evanston, IL (US);

Pieter Isabelle Roger Claes, Gentbrugge, BE;

Marlon D. Cowart, Round Lake Beach, IL (US);

Katja E. Conrath, Mechelen, BE;

Douglas Cyr, Chapel Hill, NC (US);

Elsa De Lemos, Paris, FR;

Gert Jules Hector De Wilde, Mechelen, BE;

Nicolas Desroy, Massy, FR;

Béranger Duthion, Paris, FR;

Gregory A. Gfesser, Lindenhurst, IL (US);

Romain Luc Marie Gosmini, Savigny-sur-Orge, FR;

Christopher Gaëtan Housseman, Montreuil, FR;

Koen Karel Jansen, Turnhout, BE;

Jianguo Ji, Libertyville, IL (US);

Philip R. Kym, Libertyville, IL (US);

Jean-Michel Lefrancois, Le Raincy, FR;

Oscar Mammoliti, Mechelen, BE;

Christel Jeanne Marie Menet, Brussels, BE;

Nuria Merayo Merayo, Paris, FR;

Gregory John Robert Newsome, Neuilly Plaisance, FR;

Adeline Marie Elise Palisse, Brussels, BE;

Sachin V. Patel, Round Lake, IL (US);

Mathieu Rafaël Pizzonero, Voisins le Bretonneux, FR;

Anurupa Shrestha, Vernon Hills, IL (US);

Elizabeth C. Swift, Highland Park, IL (US);

Chris Tse, Libertyville, IL (US);

Steven Emiel Van der Plas, Steenhuffel, BE;

Xueqing Wang, Northbrook, IL (US);

AbbVie S.á.r.l., Luxembourg, LU;

Galapagos NV, Mechelen, BE;